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Chronic myeloid leukemia (CML) is a cancer characterized by the overgrowth of the myeloid lineage 
of white blood cells, mainly granulocytes and their progenitors, in the bone marrow and blood. CML 
was the first cancer identified as driven by a single chromosomal translocation known as the 
Philadelphia chromosome, joining coding regions of the ABL1 gene from chromosome 9 to the break 
point cluster (BCR) gene from chromosome 22, generating the BCR-ABL fusion protein. BCR-ABL 
functions as an oncogene; the fused ABL tyrosine kinase constitutively activates a number of 
pathways that control cell growth and survival. In the 1990s, CML became the first cancer treated by 
targeted drug therapy by blocking ABL activity with a tyrosine kinase inhibitor (TKI), imatinib. 
While effective in most CML patients, some patients are refractory or develop mutations that prevent 
imatinib from working. Second generation TKIs, nilotinib and dasatinib, were originally developed 
and approved to treat patients who failed imatinib therapy, but because of promising initial clinical 
trial reports, both drugs were FDA approved for treatment of newly diagnosed patients in 2010. 
While imatinib binds to ABL in the ATP-binding domain and stabilizes the inactive conformation, 
dasatinib binds and stabilizes the active confirmation of ABL to inhibit ATP binding and kinase 
activity. Dasatinib is 325-fold more potent than imatinib in inhibiting BCR-ABL activity due to an 
enhanced binding affinity. Furthermore, dasatinib is active against a number of imatinib-resistant 
BCR-ABL mutations, except for the T315I mutation that blocks effectiveness of all TKIs. Early stage 
CML, called chronic phase (CP-CML), is readily treatable by TKIs, while disease progression to the 
more acute blast crisis CML is less sensitive to TKI treatment. 
Previous pharmaceutical-sponsored randomized trials suggested that dasatinib and nilotinib gave 
better short-term responses in newly diagnosed CP-CML patients. Lead author Dr. Jerald Radich, 
Clinical Research Division director Dr. Fred Applebaum, and Dr. Ken Kopecky from the SWOG 
Statistical Center contributed to the recent report of a multicenter clinical trial (NCT00070499) 
comparing first-line CP-CML therapy with imatinib (400 mg/kg dose) versus dasatinib (100 mg/kg 
dose). Initiated in 2006, the trial enrolled 253 patients who were randomized to either drug treatment. 
The therapeutic molecular response, as measured by sensitive PCR assays for BCR-ABL mRNA 
transcripts, was significantly better for dasatinib versus imatinib in the short term; at one year a 
1,000-fold reduction in BCR-ABL was achieved for 59% of patients treated with dasatinib versus 
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44% of imatinib-treated patients (P=0.059), and a 10,000-fold decrease in 27% versus 21% of 
patients, respectively (P=0.32). Furthermore, dasatinib treatment yielded an increased proportion of 
patients with complete cytogenetic response versus imatinib (84% versus 69%, P=0.04), as 
determined by the absence of BCR-ABL translocations in at least 20 bone marrow cells. However, 
overall survival, progression-free survival, and relapse-free survival were not statistically different for 
the two drug treatments. Importantly, dasatinib treated patients had more grade 3-4 toxicities than 
imatinib (58% versus 35%, P=0.0001), with mostly hematologic toxicities such as thrombocytopenia 
and pleural effusions with dasatinib, and fluid retention and nausea for imatinib. 
The results of this trial were comparable to other first-line CP-CML clinical trials, which show a 
significantly better molecular response to the second generation TKIs dasatinib or nilotinib versus 
imatinib. Importantly, benefits of this improved short-term molecular response to patient survival 
have not been shown. Overall, the study confirms the effective use of dasatinib in first-line therapy 
for CML as FDA-approved in 2010, however, the report emphasizes that the clinician must consider 
potential increased toxic side effects, as imatinib has a longer record for safety, as well as a reduced 
cost as imatinib moves off patent to become a generic drug. Importantly, no TKI approved for CML is 
a curative treatment, so the treatment goal is to drive CML into remission and prevent disease 
progression by lifelong treatment with TKIs. 
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Molecular response measured by detecting 
BCR-ABL transcript by quantitative reverse 
transcriptase-PCR is displayed for imatinib 
(blue) and dasatinib (red) treatment of CP-CML 
and time on study. Changes are displayed 
relative to a group-specific median baseline 
value on a log10 scale, with no change, 3-log 
and 4-log decrease from baseline show with 
horizontal dashed lines. The median reduction 
in BCR-ABL expression was 2.8 log for the 
imatinib arm and 3.3 log for the dasatinib arm 
at one year (P=0.063). Patient numbers for each 
treatment are listed at the top. 
